Selegiline transdermal system: Somerset

Current Opinion in Investigational Drugs

Volumn 3, Issue 8, 2002, Pages 1230-1233

  Mahmood, Iftekhar ^a  

^a Division of Bacterial Products   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; CYTOCHROME P450 INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG METABOLITE; ITRACONAZOLE; METHAMPHETAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; SELEGILINE;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DEPRESSION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME INHIBITION; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPERTENSION; MULTIPLE DRUG DOSE; NONHUMAN; PARKINSON DISEASE; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ANTIDEPRESSIVE AGENTS; DOPAMINE AGONISTS; HUMANS; MONOAMINE OXIDASE INHIBITORS; SELEGILINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036707267     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. 182121 Annual Report 1995 - Mylan Laboratories Inc. Mylan Laboratories Inc Annual Report 1995
2. 250573 Watson still on acquisition trail. SCRIP 1997 2234 9
3. 275389 Watson to copromote somerset Eldepryl, Warner-Lambert Zarontin. FDC Reports Pink Sheet 1997 59 41 T&G-6-T&G-7
4. 287469 Somerset Pharmaceuticals reports results of clinical trial in major depression. Somerset Pharmaceuticals Press Release 1998 May 19
5. b in human subjects. Heinonen EH, Anttila M, Nyman L, Vuorinen JA, Pyykko KA, Lammintausta RA J Clin Pharmacol 1997 37 7 602-609
6. 410848 Somerset announces submission of New Drug Application for EMSAM (Selegiline Transdermal System). Somerset Pharmaceuticals Press Release 2001 May 25
7. 448986 Phenylisopropylmethyl propinylamine (E-250), a new spectrum psychic energizer. Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B Arch Int Pharmacodyn Ther 1965 155 1 154-164
8. 448987 Pharmacokinetics and safety of selegiline transdermal system relative to single dose oral administration in the elderly. Barrett JS, Hochadel TJ, Morales RJ, Rohatagi S, DeWitt KE, Watson SK, DiSanto AR Am J Ther 1996 3 10 688-698 Describes an open-label, two-phase, cross-over study in the elderly, in which STS and metabolites of selegiline
9. 448988 Substrate- and inhibitor-related characteristiscs of human platelet monoamine oxidase. Donnelly CH, Murphy DL Biochem Pharmacol 1977 26 9 853-858
10. 448989 Dopamine is a monoamine oxidase B substrate in man. Glover V, Sandler M, Owen F, Riley GJ Nature 1977 265 5589 80-81
11. 448990 Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males. Barrett JS, Hochadel TJ, Morales RJ, Rohtagi S, DeWitt KE, Watson KS, Darnow J, Azzaro AJ, DiSanto A J Clin Pharmacol 1997 37 3 238-247
12. 448991 Pharmacokinetic aspects of I-deprenyl (selegiline) and its metabolism. Heinonen E, Antilla M, Lammintausta R Clin Pharmacol Ther 1994 56 6 742-749
13. 448992 Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. Sunderland T, Tariot PN, Cohen RM, Newhouse PA, Mellow AM, Mueller EA Psychopharmacology 1987 91 3 293-296
14. 448993 Gas chromatographic-mass spectrometric determination of plasma selegiline using a deuterated internal standard. Patrick K, Nguyen B, McCallister J J Chromatogr 1992 583 2 254-258
15. 448994 An enzymatic assay for the MAO-B inhibitor selegiline in plasma. Mahmood I, Neau SH, Mason WD J Pharm Biomed Anal 1994 12 7 895-899
16. 448995 The effect of dosing regimen and food on the bioavailability of the extensively metabolized, highly variable drug eldepryl ((R)) (selegiline hydrochloride). Barrett JS, Rohatagi S, Dewwitt KE, Morales RJ, DiSanto AR Am J Ther 1996 3 4 298-313
17. 448997 Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: Relationship of metabolism to MAO-B inhibitory potency. Yoshida T, Yamada Y, Yamamoto T, Kuroiwa Y Xenobiotica 1986 16 2 129-136
18. 448998 Selegiline percutaneous absorption in various species and metabolism by human skin. Rohtagi S, Barret JS, McDonald LJ, Morris EM, Darnow J, DiSanto AR Pharm Res 1997 14 1 50-55 Metabolism of selegiline by human skin was negligible. The dog was demonstrated to be the most appropriate species for testing the STS.
19. 448999 Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,α-dimethyl-N-propynlphenethylamine, by cytochrome P4502D6. Grace GM, Kinter MT, Macdonald TL Chem Res Toxicol 1994 7 3 286-290
20. 449000 CYP2D6 polymorphism is not crucial for the disposition of selegiline. Scheinin H, Anttila M, Dahl M.-L, Karnani H, Nyman L, Taavitsainen P, Pelkonen O, Bertilsson L 1998 64 4 402-411
21. 449002 CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. Laine K, Anttila M, Nyman L, Wahlberg A, Bertilsson L Eur J Clin Pharmacol 2001 57 1 137-142
22. 449033 Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. Kivisto K, Wang JS, Backman JT, Nyman L, Taavitsainen P, Anttila M, Neuvonen PJ Eur J Clin Pharmacol 2001 57 1 37-42
23. 449034 Is 10 milligrams selegiline essential as an adjunct therapy for the symptomatic treatment of Parkinson's disease? Mahmood I Ther Drug Monit 1998 20 6 717-721
24. B to the same extent as an oral dose of 3.4 mg.
25. 449036 L-deprenyl plus L-phenylalanine in the treatment of depression. Birkmayer W, Riederer P, Linauer W, Knoll J J Neural Transm 1984 59 1 81-87
26. 449037 Differential efficacy of L-deprenyl, a selective MAO type-B inhibitor, in endogenous and nonendegenous depression. Mann JJ, Frances A, Peselow ED, Gershon S Psychopharmacol Bull 1982 18 4 182-184
27. 449038 A placebo-controlled trial of L-deprenyl in atypical depression. McGrath PJ, Stewart JW, Harrison W, Wager S, Nunes EN, Quitkin FM Psychopharmacol Bull 1989 25 1 63-67
28. 449041 Sunderland T, Cohen RM, Molchan S, Lawlor BA, Mellow AM, Newhouse PA, Tariot PN, Meuller EA, Murphy DL High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994 51 8 607-615
29. 449043 Moclobemide and selegiline in the treatment of depression in Parkinson's disease. Steur E, Ballering L J Neurol Neurosurg Psychiatry 1997 63 4 547
30. 449044 Transdermal selegiline in HIV-associated cognitive impairment: Pilot, placebo-controlled study. Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K Neurology 2000 54 1 233-235
31. 449158 The Merck Index (12th Edition). Susan Budavari (Ed). Merck Research Laboratories, Whitehouse Station, NJ, USA 1996.
32. 449160 Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. Tipton KF, Dostert P, Strolin Benedetti M (Eds). Academic Press, London, UK 1984
33. 449221 An improved flurometric assay for brain monoamine oxidase. Morinan A, Garrat HM J Pharmacol Methods 1988 13 3 213-223
34. 449225 Quantitative determination of selegiline, desmethylselegiline, amphetamine and methamphetamine in human plasma by ion spray LC/MS/MS. Mulvana DE, Perkins JR, Henion JD Pharm Res 1993 10 (Suppl) S-331
35. 449227 Multiple dose pharmacokinetics and dose proportionality of selegiline and metabolites in healthy males following transdermal administration. Rohatagi S, Barret JS, Morales R, DeWitt KE Pharm Res 1996 13 (Suppl) S-502
36. 456735 Somerset Pharmaceutical receives 'Not-approvable' letter from FDA for EMSAM. Somerset Pharmaceuticals Press Release 2002 March 27